The multiple compression in Nike $NKE is due to their brand not having the same moat that it once was.
This market is saturated and the image doesn’t include private companies like New Balance, Gymshark, Brooks, or Vuori.
The era of social media makes it too easy to market new brands.
Nikes leadership team better make a strategic pivot to restore their brand dominance.
Defense companies have been getting relentlessly sold since the start of the Iran war. From a technical standpoint, $NOC is at a key monthly level. It's defended this since 2013 (honestly wild, what a run). Weekly and Daily views look awful though.
Does a resolution to the Iran war cause defense to catch a bid?
@DrugChannels@IQVIA_global Would be curious to see this broken down by therapeutic area.
The difference between $0 through $30 isn't a significant difference either. The fact that $0 is at 10% is obvious that cost is not the main driver in the lower OOP brackets.
I’m surprised $SABR didn’t see much price action either up or down this week. I want to see it capture a few moving averages before I consider getting long.
The agentic theme is incredibly early. It feels like a deal would be the validating catalyst needed. It will likely take several quarters to see revenue inflection